FDA GLP-1 Compounding Rules 2026: What the Shortage Resolution Actually Means for Patients

The FDA's 2026 GLP-1 compounding rules allow licensed 503A pharmacies to continue preparing patient-specific compounded semaglutide and tirzepatide for individuals with valid prescriptions, while restricting large-scale 503B production of "essentially copies" now that FDA has declared the shortages resolved. Personalized compounding remains legal; bulk copy-style manufacturing does not.

The reality is more nuanced, more manageable, and — for patients with legitimate prescriptions working with compliant pharmacies — less alarming than the headlines suggest.

This guide walks through exactly what the FDA's GLP-1 compounding rules say, what the shortage resolutions actually changed, where the legal lines currently sit, and what it all means for your prescription. We are not going to oversimplify in the optimistic direction either. Some things genuinely have changed, and patients deserve an honest account of where things stand.

What GLP-1 Compounding Is — and Why It Matters

GLP-1 receptor agonists — glucagon-like peptide-1 drugs — are a class of medications that work by mimicking a naturally occurring hormone involved in appetite regulation, blood glucose control, and metabolic signaling. The two molecules that have defined this category in recent years are semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) and tirzepatide (the active ingredient in Mounjaro and Zepbound, a dual GLP-1/GIP agonist). The FDA maintains a dedicated patient information page on medications containing semaglutide that outlines approved uses, safety communications, and known issues with unapproved sources.

Branded GLP-1 medications carry significant costs — often exceeding $1,000 per month without insurance coverage — and have faced serious, documented supply constraints since their explosive rise in demand beginning around 2022. Compounded versions of these same active ingredients, prepared by licensed pharmacies, emerged as a lower-cost alternative that expanded access to patients who would otherwise be priced out or unable to obtain the medication at all. For a deeper look at what compounded GLP-1 therapy actually is, our honest guide to compounded semaglutide explains how it differs from Ozempic and Wegovy and what to realistically expect.

Pharmacy compounding is the practice of preparing individualized medications based on specific prescriptions from licensed providers. It has a long and legitimate history in American pharmacy practice and serves critical functions: enabling custom dosing, eliminating allergens, creating alternative delivery forms, and filling gaps when commercially manufactured drugs are unavailable. Our guide to compounded medication safety walks through the differences between 503A and 503B facilities and the USP standards every legitimate pharmacy must meet. Compounding is regulated under federal law and by state boards of pharmacy.

During the period of FDA-declared drug shortages for semaglutide and tirzepatide, compounding pharmacies operated under explicit legal authorization to prepare these medications at scale. When the FDA began resolving those shortages, the authorization structure changed — but it did not disappear entirely. Understanding why requires understanding the underlying legal framework.

The Legal Framework: 503A vs. 503B Explained

Two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) govern pharmacy compounding in the United States. They create distinct categories with different rules, different oversight structures, and — critically — different implications when it comes to GLP-1 compounding. For primary-source context, the FDA's own Compounding Questions and Answers page walks through the statutory framework in plain language.

Section 503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act governs traditional compounding pharmacies — the classic model in which a licensed pharmacist prepares a medication based on a valid prescription written by a licensed prescriber for a specific, identified patient.

Under 503A, a compounding pharmacy:

• Must compound based on a valid prescription for an individual patient
• Cannot compound a product that is essentially a copy of a commercially available drug — unless there is a documented patient-specific reason why the commercial product does not meet that patient's clinical needs (for example: required customization of dose, need for a different delivery form, or documented allergy to an excipient in the commercial product)
• Is regulated primarily by the state board of pharmacy where it holds a license
• Must use bulk drug substances that meet USP (United States Pharmacopeia) or NF (National Formulary) standards
• Cannot distribute large volumes across state lines as a commercial manufacturer would

503A pharmacies have historically been the backbone of personalized compounding — preparing medications tailored to individuals. During the GLP-1 shortages, a specific exception in Section 503A allowed them to legally compound semaglutide and tirzepatide even though those drugs are commercially available, because drug shortages create a recognized clinical gap that compounding is permitted to fill.

Section 503B: Outsourcing Facilities

Section 503B was created by the Drug Quality and Security Act (DQSA) of 2013, passed in the wake of the 2012 New England Compounding Center (NECC) meningitis outbreak — a tragedy that killed 64 people and exposed the risks of large-scale compounding without adequate federal oversight.

503B outsourcing facilities operate differently from 503A pharmacies in several important respects:

• They can compound medications in large batches without individual patient prescriptions (anticipatory compounding)
• They must comply with FDA current Good Manufacturing Practices (cGMP) — the same manufacturing quality standards applied to large pharmaceutical companies
• They are subject to direct FDA registration and inspection
• They must report adverse events to the FDA
• They can distribute across state lines more broadly than 503A pharmacies

503B facilities became major suppliers of compounded semaglutide and tirzepatide during the shortage period, because their ability to prepare large batches without individual prescriptions made them the most efficient channel for meeting the massive surge in demand. When the FDA resolved the shortages, 503B facilities faced the most significant and immediate restrictions, as the specific shortage exception that authorized their large-scale compounding of these drugs expired.

The Shortage Rule: How the FDA Authorized Mass Compounding

The legal foundation for shortage-era GLP-1 compounding is found in specific provisions of the FD&C Act that address what happens when commercially manufactured drugs are unavailable.

Under federal law, compounding pharmacies and outsourcing facilities can legally compound drugs that are on the FDA's Drug Shortage List. This exception overrides the normal restriction against compounding "essentially a copy" of a commercially available drug — because when a drug is on the shortage list, it is by definition not adequately available commercially.

For 503A pharmacies, this means: when semaglutide or tirzepatide is on the shortage list, a licensed 503A pharmacy can compound it for a patient with a valid prescription, even though brand-name versions technically exist — because those versions are not adequately accessible.

For 503B outsourcing facilities, the shortage exception goes further: it permits the preparation of large batch quantities distributed to healthcare facilities without individual prescriptions, which would otherwise be prohibited.

The key legal event, therefore, is what happens when the FDA removes a drug from the shortage list. At that point, the shortage-based exception expires. The compounding rules revert to their baseline state — which does not categorically prohibit compounding, but does impose specific requirements that were more loosely observed during the shortage period.

Timeline: Key FDA Decisions from 2022 to 2026

• 2022 — Demand Surge Begins
  GLP-1 demand explodes; supply chains strained
  Ozempic, originally approved for type 2 diabetes, sees explosive off-label demand for weight management. Supply constraints begin. Patients and providers look for alternatives.
• 2022–2023 — FDA Shortage Declarations
  Semaglutide and tirzepatide added to FDA Drug Shortage List
  The FDA officially declares shortages of both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). 503A pharmacies and 503B outsourcing facilities gain clear legal authorization to compound these molecules. The compounded GLP-1 market expands rapidly.
• October 2023 — FDA Warning Letters Begin
  FDA signals concern about compounding practices and scale
  FDA issues warning letters and guidance targeting specific practices including: compounding with unapproved salts, misleading labeling, and distribution by entities not meeting pharmacy standards. The agency begins distinguishing between compliant and non-compliant compounders.
• Late 2024 — Semaglutide Shortage Resolved
  FDA removes semaglutide from the Drug Shortage List
  The FDA determines that semaglutide is no longer in shortage, meaning the shortage-based compounding exception expires. 503B outsourcing facilities receive a compliance timeline to wind down bulk compounding of semaglutide. 503A pharmacies must ensure any continued compounding of semaglutide meets individual patient-specific clinical justification requirements.
• Late 2024 — Tirzepatide Shortage Declared Resolved
  FDA removes tirzepatide from shortage list; industry groups challenge
  FDA determines tirzepatide supply is adequate. Compounding industry coalitions file legal challenges, arguing the shortage determination was premature. Federal courts grant temporary injunctive relief in some cases, creating a period of delayed enforcement while litigation proceeds.
• 2025 — Litigation and Evolving Enforcement
  Courts, Congress, and FDA navigate the transition
  Multiple federal court cases produce varying results. Some injunctions are upheld, some are not. FDA issues further guidance documents clarifying the 503A patient-specific exception. Congressional interest in the policy increases as millions of patients raise access concerns. Enforcement of 503B restrictions on tirzepatide proceeds with some delay.
• 2026 — Current State
  Shortage-based bulk compounding effectively ended; patient-specific compounding continues under conditions
  The era of unencumbered shortage-based bulk compounding of semaglutide and tirzepatide is effectively over. Compliant 503A pharmacies compounding under patient-specific prescriptions with documented clinical justification continue to operate. The legal and policy landscape remains active.

Semaglutide Status in 2026

The semaglutide picture is the cleaner of the two. With the shortage resolved, the default prohibition on compounding essentially a copy of a commercially available drug is back in effect. This means:

• 503B outsourcing facilities cannot continue bulk compounding semaglutide on the basis of shortage authorization. Compliance deadlines applied and have passed.
• 503A pharmacies cannot simply continue to compound semaglutide for any patient who requests it, in the same way they could during the shortage. However, 503A pharmacies can legally compound semaglutide for an individual patient when a licensed prescriber has documented patient-specific clinical reasons why the commercially available product does not meet that patient's needs.

What constitutes a valid patient-specific justification? The FDA has not published an exhaustive list, but the relevant principles under 503A include situations such as:

• The patient requires a dose or dose increment that is not available in the commercial formulation
• The patient has a documented allergy or sensitivity to an ingredient (excipient, preservative, etc.) present in the commercial product but not in the compounded version
• A licensed physician has made a clinical determination that the patient's specific needs are better served by a compounded formulation — and has documented that determination in the prescription

Crucially, price alone is not a recognized clinical justification for compounding a drug that is essentially a copy of a commercially available product. The legal framework was designed around clinical access, not cost access. That said, many patients have legitimate clinical reasons — and providers who understand the current rules can document those reasons appropriately.

Tirzepatide Status in 2026

The tirzepatide situation has followed a more turbulent path due to active litigation. Compounding industry groups argued — with some initial success in federal court — that the FDA's shortage determination was made prematurely and without adequate consideration of patient access. These legal challenges resulted in temporary injunctive relief that delayed FDA enforcement against some 503B compounders of tirzepatide into 2025.

As of 2026, those enforcement delays have largely run their course. The underlying FDA position — that tirzepatide is no longer in shortage and shortage-based compounding authorization has expired — has not been reversed by any court. The practical implication is similar to semaglutide: bulk compounding by 503B facilities is no longer authorized on shortage grounds, and 503A compounding requires patient-specific justification.

It is worth noting that tirzepatide's unique pharmacology as a dual GLP-1/GIP receptor agonist means there is genuinely no commercially available branded alternative that produces exactly the same mechanism of action. Our side-by-side comparison of tirzepatide and semaglutide breaks down the mechanism, clinical trial data, and dosing differences in detail. Some providers have argued this creates legitimate individualized clinical rationale for patients whose protocols require a GLP-1/GIP dual agonist at a dose or formulation not available commercially. This is a nuanced clinical and legal question that should be addressed between the patient and their prescribing provider.

What "Compounding Is Not Illegal" Actually Means

One of the most important distinctions in this entire conversation is the difference between these two statements:

• "Compounded GLP-1 medications are illegal."
• "The shortage-based authorization that permitted large-scale compounding of GLP-1 medications without individual clinical justification has expired."

The first statement is false. The second is accurate. They are not the same thing, and conflating them creates unnecessary alarm for patients who have legitimate, properly documented prescriptions working through compliant pharmacies.

Compounding pharmacy is legal in the United States. It has been legal for over a century. Section 503A of the FD&C Act specifically protects the right of licensed pharmacies to compound patient-specific medications. No FDA action has repealed 503A or declared compounding pharmacies illegal.

What the FDA has done — and has clear authority to do — is enforce the specific conditions under which compounding of particular drugs is permitted. When semaglutide was on the shortage list, broad compounding was permitted because the shortage exception applied. When the shortage was resolved, that exception expired. The baseline 503A rules came back into effect. Those rules permit compounding with appropriate patient-specific justification.

The difference matters enormously for patients. An individual with a valid prescription from a licensed provider, working with a 503A pharmacy that meets state licensing standards and compounds on the basis of documented patient-specific clinical reasons, is in a legal framework. That is not the same legal position as a 503B outsourcing facility that continued to produce large batches of semaglutide for distribution to weight loss clinics after the shortage was resolved.

Addressing Common Patient Fears

"Will my prescription suddenly stop?"

Not automatically, and not without warning. Whether your access continues depends on the specific pharmacy you are using, the documentation your prescriber has provided, and whether your prescriber is actively monitoring the pharmacy's compliance posture. If you are receiving compounded semaglutide or tirzepatide from a 503A pharmacy with an individual prescription and your prescriber has documented patient-specific clinical justification, your situation is legally different from a patient whose provider was simply ordering through a 503B outsourcing facility that can no longer legally compound these drugs in bulk.

The practical advice: have an explicit conversation with your prescribing provider. Ask them to explain how your prescription is structured and what the pharmacy's current compliance status is. A good provider will be able to answer this clearly.

"Is this a ban?"

No. The word "ban" implies a categorical prohibition on a substance or practice. No such ban exists for compounded semaglutide or tirzepatide. What exists is the expiration of a specific exception — the shortage authorization — that had temporarily broadened the conditions under which these specific drugs could be compounded. The underlying compounding framework, which permits patient-specific compounding with appropriate clinical justification, remains fully in place.

"Is what I've been taking illegal?"

Medications compounded during the shortage period, when proper authorization existed, were legal at the time they were prepared and dispensed. The FDA does not retroactively criminalize patients for accessing properly compounded medications during a period when that compounding was authorized. No patient has faced legal jeopardy for using compounded GLP-1 medications. The FDA's enforcement actions have been directed at pharmacies and facilities — specifically those that failed to comply with applicable regulations — not at individual patients.

"Are the results I've gotten real? Will they disappear?"

The clinical results of GLP-1 therapy are well-established in the published literature and do not change based on regulatory status. If you have experienced meaningful progress on a GLP-1 protocol, that progress is real. The regulatory question is about access going forward, not about the validity of your experience. Maintaining results typically requires continued treatment — which makes accessing a compliant ongoing prescription path important to address proactively with your provider.

"Should I stockpile medication?"

This is a clinical question that should be discussed with your prescribing provider, not a regulatory strategy to pursue independently. Stockpiling does not solve the underlying access question and may create safety concerns around storage, beyond-use dating, and changes to your protocol over time. The more productive path is to work with your provider to understand your current compliance status and identify a sustainable, properly structured prescription arrangement.

How to Evaluate Whether Your Protocol Is Compliant

If you are currently on compounded semaglutide or tirzepatide, here is a practical framework for understanding where your situation stands:

Question 1: What type of pharmacy compounds my medication?

Ask your provider or your pharmacy directly: are you a 503A compounding pharmacy or a 503B outsourcing facility? The answer significantly shapes the applicable rules. 503A pharmacies operating under individual patient prescriptions with clinical justification have more flexibility under current law than 503B facilities that relied on shortage-based authorization for bulk compounding.

Question 2: Does my prescription include documented clinical justification?

For a 503A pharmacy to legally compound semaglutide or tirzepatide post-shortage, the prescription should reflect documented patient-specific clinical reasons for the compounded version rather than the commercial alternative. Ask your provider whether your chart and prescription documentation reflects this. If they are simply writing prescriptions the same way they did during the shortage without updating the clinical documentation, that is a compliance gap worth addressing.

Question 3: Is my pharmacy in good standing with its state board?

Every licensed pharmacy has a license number verifiable through its state board of pharmacy. You can confirm that your pharmacy holds an active, unrestricted license in good standing in the state where it operates. Disciplinary actions, suspensions, and consent orders are public record and searchable through state board websites.

Question 4: Has my pharmacy communicated any changes to its operations?

Transparent, compliant pharmacies communicate proactively when regulatory changes affect their operations. If you have heard nothing — particularly if you are with a pharmacy that was clearly operating at high volume during the shortage period — it is worth asking directly whether anything has changed about how they are compounding your medication and whether the pharmacy has received any FDA notices or enforcement communications.

Question 5: Is my prescriber actively engaged?

The 503A framework requires genuine physician engagement — not a rubber-stamp prescription renewal system. Your prescriber should be actively monitoring your progress, adjusting your protocol as needed, and able to explain the clinical rationale for your current regimen. If your "prescriber" relationship consists of an intake questionnaire and automatic refills with no meaningful clinical contact, that arrangement may not meet the requirements for patient-specific compounding justification.

Frequently Asked Questions

Is compounded semaglutide still legal in 2026?

Compounded semaglutide is not categorically illegal — but the legal landscape changed when the FDA resolved the semaglutide shortage in late 2024. With the shortage resolved, 503A pharmacies may no longer compound semaglutide in large batches based solely on anticipated demand. However, a licensed 503A pharmacy can still legally compound semaglutide for an individual patient when a licensed prescriber provides a valid prescription with patient-specific clinical justification for why commercially available semaglutide does not meet that patient's needs. 503B outsourcing facilities face more restrictive conditions. The bottom line: if you have a valid prescription with appropriate clinical justification from a licensed provider working with a compliant pharmacy, you are in a legal framework. Seek out transparent telehealth platforms that work exclusively with properly licensed pharmacies.

Is compounded tirzepatide still legal in 2026?

The status of compounded tirzepatide has been more fluid than semaglutide. The FDA declared the tirzepatide shortage resolved in late 2024, which triggered restrictions on bulk compounding by 503B outsourcing facilities. Litigation by compounding industry groups temporarily delayed enforcement, and the situation continued to evolve through 2025. As of 2026, the core legal principle is the same as semaglutide: shortage-based bulk compounding is no longer permitted now that the shortage is resolved, but patient-specific compounding by a 503A pharmacy with a valid prescription and documented individual clinical justification can still be legal under federal law. State law adds additional layers. Patients should work with a licensed telehealth provider and a compliant pharmacy and seek direct clarity on the current status, as enforcement guidance can shift.

What is the difference between a 503A pharmacy and a 503B outsourcing facility for GLP-1 compounding?

Section 503A governs traditional compounding pharmacies, which compound patient-specific medications based on individual prescriptions from licensed providers. Section 503B governs outsourcing facilities, which can compound larger batches without individual prescriptions and distribute more broadly but must meet cGMP manufacturing standards and are directly regulated by the FDA. During the GLP-1 shortages, both 503A and 503B entities could legally compound semaglutide and tirzepatide. After the FDA resolved the shortages, 503B facilities faced an earlier and stricter deadline to stop shortage-based compounding, while 503A pharmacies have more flexibility when compounding based on legitimate individual prescriptions with documented clinical justification.

Will my compounded GLP-1 prescription be cut off?

Not automatically. Whether your access continues depends on several factors: which drug you are prescribed (semaglutide vs. tirzepatide), the type of pharmacy compounding it (503A vs. 503B), and whether your prescriber has documented a valid clinical justification for why the compounded version — rather than the commercially available brand — is appropriate for you specifically. Patients currently on protocols prescribed by licensed physicians working with compliant 503A pharmacies are not necessarily facing immediate disruption. The best step is to have a direct conversation with your prescribing provider about the pharmacy's compliance status and whether your prescription documentation supports continued access.

What should I do if I'm currently on compounded semaglutide or tirzepatide?

Do not make any medication changes without speaking to your prescribing provider first. Ask your provider: (1) Is the pharmacy we use a licensed 503A pharmacy in good standing with its state board? (2) Does my prescription include documentation of patient-specific clinical justification? (3) Has the pharmacy confirmed its compliance with current FDA guidance? If your current arrangement clearly meets those criteria, there may be no immediate disruption. If your provider cannot clearly answer those questions, it may be worth seeking care from a transparent, compliance-first telehealth platform that can give you a direct account of how your prescription is structured.